Immunotherapy may benefit people with leptomeningeal carcinomatosis, a rare but serious complication of cancer that has spread to the brain and/or spinal cord. Treatment with immune checkpoint inhibitors caused notable changes in the characteristics of immune cells within the cerebrospinal fluid of patients. In a phase II clinical trial, treatment extended overall survival in patients compared with historical controls.